New drug aims to reduce kidney damage in IgAN patients
NCT ID NCT07502638
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental drug called FXS6837 in 60 adults with IgA nephropathy, a kidney disease. Participants will receive either the drug or a placebo for about 6 months. The main goal is to see if the drug lowers protein in the urine, a sign of kidney damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGAN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill slow kidney damage in IgA nephropathy?
- Can a gut metabolite shield the kidneys in IgA nephropathy?
- Can a new pill protect kidneys from IgA nephropathy?
- New pill aims to tame kidney disease in Long-Term trial
- New pill aims to slow kidney disease in IgA nephropathy patients
- New drug aims to protect kidneys in IgA nephropathy patients